A kit of parts for use in treatment of tissue by a contained plasma and/or plasma products is disclosed. The kit of parts includes a plasma generating device for use with a membrane dressing attached to tissue requiring treatment. The plasma generating device comprises a first cavity with an opening at one end formed between a grounded electrode and a cathode such that, in use, an arc discharge between the cathode and the grounded electrode ionizes a feed gas to produce at the open end a thermal plasma. Furthermore, the plasma generating device also comprises a second cavity with an opening at one end formed between a high voltage electrode and a grounded electrode such that, in use, a dielectric barrier discharge between the high voltage electrode and grounded electrode ionizes a feed gas to produce at the open end a non-thermal plasma. The membrane dressing is suitable for covering tissue in use, such as a diabetic ulcer, and comprises a sheet of impermeable material configured for forming a plasma containment compartment adjacent to the tissue. The membrane dressing also comprises one or more input connectors configured to admit plasma and/or plasma products through the membrane dressing. The plasma generating device and the one or more input convectors of the membrane dressing are configured to allow the plasma generating device and the input connector to be directly coupled or indirectly coupled through a connector tube to allow fluid communication of the plasma and/or plasma products produced at the openings of the cavities of the plasma generating device through the membrane dressing to, in use, allow conduction of the produced plasma into the membrane dressing. Advantages of such a kit of parts may be that the membrane dressing does not need to be removed to inspect the progress of the wound, nor does it need to be removed and replaced to manage the exudate. Such advantages helps to mitigate the problems of wound aggravation and maceration typically associated with well-known wound dressings, and also helps to encourage and facilitate wound healing.

The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.

A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer, glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam and a method of preparing said sterile pharmaceutical dosage form.

A container includes a first wall made of a polymeric material, a second wall made of a polymeric material, and a plurality of elongated baffles, spacers or seam lines formed between the first wall and the second wall to form a plurality of separate fluid flow paths. Each of the plurality of fluid flow paths are separated from the other fluid flow paths by at least one of the baffles, spacers or seam lines. Each of the plurality of fluid flow paths have a first end in fluid communication with an inlet and have a second end in fluid communication with an outlet.

The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained.

Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.

The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained.

The present disclosure provides methods for reducing bioburden on a tissue product, as well as the tissue products produced according to the disclosed methods. In particular, the disclosure relates to methods of electroporating tissue in the presence of one or more bactericides in order to reduce bioburden. The methods allow for reduced exposure to electrical energy and/or bactericide while reducing bioburden.

A plasma generating device that utilizes a cold plasma to contain and direct a stream of electrons with a hand held nozzle to enhance healing of wounds and skin surface abnormalities, and to kill pathogens on skin surfaces in humans and animals wounds, abnormalities and pathogens.

Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.